Pharmaceutical Industry Struggles Prompt the Small to follow the Big to BRIC Countries for Clinical Trials - India Oncology Trials Growing Fastest

A comprehensive analysis by Translational Medicine India (TMI) reveals that India, Russia, and Brazil have attracted more clinical trials sponsored by western drug developers than any other emerging countries in the last three years, with India the fastest growing. End Quote

Boston, MA-NH (1888PressRelease) November 13, 2009 - According to a comprehensive analysis released by Translational Medicine India (TMI) today, in the latest full three year period, India, Russia, and Brazil have attracted more western pharma clinical trials than any other emerging countries. The report findings highlight the significant role of the BRIC countries (Brazil, Russia, India, and China) in the clinical development activities of western pharmaceutical companies. According to this analysis, Phase II and Phase III trials by drug developers of all sizes have more than doubled between 2005 and 2008, with India growing fastest at 26% per year.

The findings are based on an analysis of over 3000 trials sponsored by western pharmaceutical companies which enrolled patients in BRIC countries. Data on these trials was collected from the Clintrials.gov database.

According to the analysis, trials sponsored by non-top 50 pharmaceutical companies were the fastest growing types of trials in the BRIC countries, although both large and small companies increased their BRIC country clinical trial activities substantially over the most recent four year period. Phase II and III trials sponsored by small and mid-size western pharma grew fastest in India which saw a 35% annual growth. Next fastest was Brazil at 17%.

The analysis also finds that Russia and India was favored for Proof of Concept (POC) studies, accounting for 75% of the Phase II studies conducted in BRIC countries. The growth rate for these studies was significant in each country, growing at 28% per year in India and 13% per year in Russia.

“The acceleration of clinical development activities to these large countries which have undergone rapid economic development indicates that the initial experience there by large pharma have validated them for smaller companies,” said Eric Meyers, consultant to TMI and the leader of the analysis. “The data on POC studies is particularly interesting indicating that both large and small companies understand that speed and cost advantages combined with global standards can create great value at this critical stage. It is clear that many smaller companies, which live and die by being innovative, have caught on to this.”

A copy of the analysis is available at http://www.transmedindia.com/download2.

About Translational Medicine India
Translational Medicine India (TMI) is U.S. headquartered clinical CRO that executes global standard clinical trials and provides a range of other clinical studies services in India through its India organization. TMI was formed in 2004 in order to make available to western clinical researchers the advantages of conducting clinical trials in India. The company combines western expertise in trial design and implementation with deep understanding of Indian expertise and practices.

Additional information can be found at http://www.transmedindia.com

Contact:
Eric Meyers
Translational Medicine India
P: +1 617-500-3625

###

Visit Translational Medicine India - Tmi Website

space